Takeda Buys Global Rights To Develop Actos API For Alzheimer’s
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical bought exclusive global technology rights from U.S.-based Zinfandel Pharmaceuticals to develop and market a treatment for Alzheimer's disease